A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

Breakthrough study could lead to new treatments as experts explore how skin fungi trigger debilitating skin condition ...

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a ...

Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

A team of researchers led by the University of Exeter have been awarded a £3.3 million grant by the Medical Research Council ...

If you work in healthcare, food service or cleaning, where frequent handwashing and exposure to irritants are common, chances ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...

Nektar, which accused Lilly of making errors in its analysis of the data, forged ahead with the programme and started the ...

Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.

A team led by the University of Exeter, and including researchers from King's College London, has been awarded a £3.3 million ...

The Food and Drug Administration in February granted fast track designation for rezpegaldesleukin to treat adults and pediatric patients 12 years and up with moderate to severe atopic dermatitis, the ...